{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T03:48:28Z","timestamp":1790221708392,"version":"4.1.0"},"reference-count":48,"publisher":"Hindawi Limited","issue":"3","license":[{"start":{"date-parts":[[2014,3,17]],"date-time":"2014-03-17T00:00:00Z","timestamp":1395014400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2014,3,17]],"date-time":"2014-03-17T00:00:00Z","timestamp":1395014400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Pharm Ther"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1111\/jcpt.12148","type":"journal-article","created":{"date-parts":[[2014,3,17]],"date-time":"2014-03-17T08:01:53Z","timestamp":1395043313000},"page":"307-313","source":"Crossref","is-referenced-by-count":19,"title":["Safety profiles of adalimumab, etanercept and infliximab: a pharmacovigilance study using a measure of disproportionality in a database of spontaneously reported adverse events"],"prefix":"10.1155","volume":"39","author":[{"given":"D.","family":"Mendes","sequence":"first","affiliation":[{"name":"CHAD - Centre for Health Technology Assessment and Drug Research; AIBILI - Association for Innovation and Biomedical Research on Light; Coimbra Portugal"},{"name":"Central Portugal Regional Pharmacovigilance Unit; AIBILI - Association for Innovation and Biomedical Research on Light; Coimbra Portugal"},{"name":"School of Pharmacy; University of Coimbra; Coimbra Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Alves","sequence":"additional","affiliation":[{"name":"CHAD - Centre for Health Technology Assessment and Drug Research; AIBILI - Association for Innovation and Biomedical Research on Light; Coimbra Portugal"},{"name":"Central Portugal Regional Pharmacovigilance Unit; AIBILI - Association for Innovation and Biomedical Research on Light; Coimbra Portugal"},{"name":"School of Pharmacy; University of Coimbra; Coimbra Portugal"},{"name":"Health Sciences Research Centre; University of Beira Interior; Covilh\u00e3 Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Batel-Marques","sequence":"additional","affiliation":[{"name":"CHAD - Centre for Health Technology Assessment and Drug Research; AIBILI - Association for Innovation and Biomedical Research on Light; Coimbra Portugal"},{"name":"Central Portugal Regional Pharmacovigilance Unit; AIBILI - Association for Innovation and Biomedical Research on Light; Coimbra Portugal"},{"name":"School of Pharmacy; University of Coimbra; Coimbra Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"98","published-online":{"date-parts":[[2014,3,17]]},"reference":[{"key":"10.1111\/jcpt.12148-BIB0001|jcpt12148-cit-0001","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/nrrheum.2011.145","article-title":"Safety of biologic therapy in rheumatoid arthritis","volume":"7","author":"Woodrick","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"10.1111\/jcpt.12148-BIB0002|jcpt12148-cit-0002","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0378-5173(03)00376-4","article-title":"Shifting paradigms: biopharmaceuticals versus low molecular weight drugs","volume":"266","author":"Crommelin","year":"2003","journal-title":"Int J Pharm"},{"key":"10.1111\/jcpt.12148-BIB0003|jcpt12148-cit-0003","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1385\/MB:27:1:59","article-title":"Preclinical safety testing of biotechnology-derived pharmaceuticals: understanding the issues and addressing the challenges","volume":"27","author":"Brennan","year":"2004","journal-title":"Mol Biotechnol"},{"key":"10.1111\/jcpt.12148-BIB0004|jcpt12148-cit-0004","doi-asserted-by":"crossref","first-page":"811","DOI":"10.2165\/11316550-000000000-00000","article-title":"Pharmacovigilance of biopharmaceuticals: challenges remain","volume":"32","author":"Giezen","year":"2009","journal-title":"Drug Saf"},{"key":"10.1111\/jcpt.12148-BIB0005|jcpt12148-cit-0005","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2174\/138920006774832604","article-title":"Early development of therapeutic biologics-pharmacokinetics","volume":"7","author":"Baumann","year":"2006","journal-title":"Curr Drug Metab"},{"key":"10.1111\/jcpt.12148-BIB0006|jcpt12148-cit-0006","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1517\/17460440903443410","article-title":"Challenges of general safety evaluations of biologics compared to small molecule pharmaceuticals in animal models","volume":"5","author":"Dixit","year":"2010","journal-title":"Expert Opin Drug Discov"},{"key":"10.1111\/jcpt.12148-BIB0007|jcpt12148-cit-0007","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1503\/cmaj.091391","article-title":"A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview","volume":"181","author":"Singh","year":"2009","journal-title":"CMAJ"},{"key":"10.1111\/jcpt.12148-BIB0008|jcpt12148-cit-0008","doi-asserted-by":"crossref","first-page":"e30275","DOI":"10.1371\/journal.pone.0030275","article-title":"Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis","volume":"7","author":"Aaltonen","year":"2012","journal-title":"PLoS One"},{"key":"10.1111\/jcpt.12148-BIB0009|jcpt12148-cit-0009","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/9781118707999.ch6","volume-title":"Textbook of pharmacoepidemiology","author":"Madre","year":"2006"},{"key":"10.1111\/jcpt.12148-BIB0010|jcpt12148-cit-0010","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1007\/s00228-013-1564-y","article-title":"Sources of information used by regulatory agencies on the generation of drug safety alerts","volume":"69","author":"Alves","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1111\/jcpt.12148-BIB0011|jcpt12148-cit-0011","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1111\/jcpt.12148-BIB0012|jcpt12148-cit-0012","doi-asserted-by":"crossref","first-page":"615","DOI":"10.2165\/00002018-200730070-00008","article-title":"You've found a safety signal-now what?: regulatory implications of industry signal detection activities","volume":"30","author":"Kahn","year":"2007","journal-title":"Drug Saf"},{"key":"10.1111\/jcpt.12148-BIB0013|jcpt12148-cit-0013","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/pds.995","article-title":"Disproportionality analyses of spontaneous reports","volume":"13","author":"Hennessy","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1111\/jcpt.12148-BIB0014|jcpt12148-cit-0014","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1111\/jcpt.12148-BIB0015|jcpt12148-cit-0015","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1111\/jcpt.12148-BIB0016|jcpt12148-cit-0016","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1007\/s10067-013-2256-9","article-title":"Safety of biologics approved for treating rheumatoid arthritis: analysis of spontaneous reports of adverse events","volume":"32","author":"Mendes","year":"2013","journal-title":"Clin Rheumatol"},{"key":"10.1111\/jcpt.12148-BIB0017|jcpt12148-cit-0017","unstructured":"Infarmed The National Pharmacovigilance System 2012 http:\/\/extranet.infarmed.pt\/page.seram.frontoffice.seramaboutpage?wmp_tc=1396715&wmp_rt=render&requestID=1e6c57b0-8c86-4890-aa2d-1cb2192cad91"},{"key":"10.1111\/jcpt.12148-BIB0018|jcpt12148-cit-0018","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Medical Dictionary for Regulatory Activities (MedDRA) 2013 http:\/\/www.ich.org\/products\/meddra.html"},{"key":"10.1111\/jcpt.12148-BIB0019|jcpt12148-cit-0019","unstructured":"Maintenance and Support Services Organization (MSSO) Medical Dictionary for Regulatory Activities (MedDRA) 2013 http:\/\/www.meddramsso.com\/"},{"key":"10.1111\/jcpt.12148-BIB0020|jcpt12148-cit-0020","unstructured":"Cabrita da Silva J Soares MA Martins SO Rea\u00e7\u00f5es Adversas a Medicamentos: An\u00e1lise da base de dados do Sistema Nacional de Farmacovigil\u00e2ncia (SVIG) 2009-2011"},{"key":"10.1111\/jcpt.12148-BIB0021|jcpt12148-cit-0021","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2165\/00002018-200326050-00001","article-title":"Application of quantitative signal detection in the Dutch spontaneous reporting system for adverse drug reactions","volume":"26","author":"Puijenbroek","year":"2003","journal-title":"Drug Saf"},{"key":"10.1111\/jcpt.12148-BIB0022|jcpt12148-cit-0022","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.2146\/ajhp120665","article-title":"Safety profile of antiviral medications: a pharmacovigilance study using the Italian spontaneous-reporting database","volume":"70","author":"Pugi","year":"2013","journal-title":"Am J Health Syst Pharm"},{"key":"10.1111\/jcpt.12148-BIB0023|jcpt12148-cit-0023","doi-asserted-by":"crossref","first-page":"865","DOI":"10.2165\/11538330-000000000-00000","article-title":"Mapping the safety profile of biologicals: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase","volume":"33","author":"Giezen","year":"2010","journal-title":"Drug Saf"},{"key":"10.1111\/jcpt.12148-BIB0024|jcpt12148-cit-0024","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.autrev.2011.04.010","article-title":"Anti-TNF therapy: safety aspects of taking the risk","volume":"10","author":"Rosenblum","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1111\/jcpt.12148-BIB0025|jcpt12148-cit-0025","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1136\/ard.2006.062760","article-title":"Time-dependent increase in risk of hospitalization with infection among Swedish RA patients treated with TNF antagonists","volume":"66","author":"Askling","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/jcpt.12148-BIB0026|jcpt12148-cit-0026","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/rheumatology\/keq242","article-title":"Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6\u00a0months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly","volume":"50","author":"Galloway","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1111\/jcpt.12148-BIB0027|jcpt12148-cit-0027","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.3899\/jrheum.101009","article-title":"Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety","volume":"38","author":"Komano","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1111\/jcpt.12148-BIB0028|jcpt12148-cit-0028","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.autrev.2012.06.008","article-title":"Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry","volume":"12","author":"Atzeni","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1111\/jcpt.12148-BIB0029|jcpt12148-cit-0029","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1136\/annrheumdis-2012-201338","article-title":"Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry","volume":"72","author":"Dartel","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/jcpt.12148-BIB0030|jcpt12148-cit-0030","doi-asserted-by":"crossref","first-page":"460","DOI":"10.4236\/jct.2013.43A056","article-title":"Biological therapy and risk of malignancies: a literature review","volume":"4","author":"Sandri","year":"2013","journal-title":"J Cancer Ther"},{"key":"10.1111\/jcpt.12148-BIB0031|jcpt12148-cit-0031","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1002\/art.24941","article-title":"Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?","volume":"60","author":"Askling","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1111\/jcpt.12148-BIB0032|jcpt12148-cit-0032","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/acr.20129","article-title":"Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British society for rheumatology biologics register","volume":"62","author":"Dixon","year":"2010","journal-title":"Arthritis Care Research"},{"key":"10.1111\/jcpt.12148-BIB0033|jcpt12148-cit-0033","doi-asserted-by":"crossref","first-page":"R5","DOI":"10.1186\/ar2904","article-title":"Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT","volume":"12","author":"Strangfeld","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1111\/jcpt.12148-BIB0034|jcpt12148-cit-0034","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/rheumatology\/ket333","article-title":"Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data","volume":"53","author":"Morgan","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1111\/jcpt.12148-BIB0035|jcpt12148-cit-0035","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1001\/2012.jama.10857","article-title":"Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis","volume":"308","author":"Lopez-Olivo","year":"2012","journal-title":"JAMA"},{"key":"10.1111\/jcpt.12148-BIB0036|jcpt12148-cit-0036","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/rheumatology\/kes350","article-title":"Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population","volume":"52","author":"Mercer","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"10.1111\/jcpt.12148-BIB0037|jcpt12148-cit-0037","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1136\/gut.2008.163683","article-title":"Dermatological complications and safety of anti-TNF treatments","volume":"58","author":"Kerbleski","year":"2009","journal-title":"Gut"},{"key":"10.1111\/jcpt.12148-BIB0038|jcpt12148-cit-0038","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/jcpt.12045","article-title":"Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritis","volume":"38","author":"F\u00e9nix-Caballero","year":"2013","journal-title":"J Clin Pharm Ther"},{"key":"10.1111\/jcpt.12148-BIB0039|jcpt12148-cit-0039","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.reuma.2012.04.007","article-title":"Skin lesions and treatment with tumor necrosis factor alpha antagonists","volume":"9","author":"Hern\u00e1ndez","year":"2013","journal-title":"Reumatol Clin"},{"key":"10.1111\/jcpt.12148-BIB0040|jcpt12148-cit-0040","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1136\/ard.2007.072967","article-title":"Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis","volume":"67","author":"Takeuchi","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/jcpt.12148-BIB0041|jcpt12148-cit-0041","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s10067-009-1169-0","article-title":"Bronchospasm associated with anti-TNF treatment","volume":"28","author":"Dubey","year":"2009","journal-title":"Clin Rheumatol"},{"issue":"Suppl 1","key":"10.1111\/jcpt.12148-BIB0042|jcpt12148-cit-0042","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/j.amjmed.2013.09.008","article-title":"Recognition and first-line treatment of anaphylaxis","volume":"127","author":"Lieberman","year":"2014","journal-title":"Am J Med"},{"key":"10.1111\/jcpt.12148-BIB0043|jcpt12148-cit-0043","first-page":"1325","article-title":"A practical guide to anaphylaxis","volume":"68","author":"Tang","year":"2003","journal-title":"Am Fam Physician"},{"key":"10.1111\/jcpt.12148-BIB0044|jcpt12148-cit-0044","unstructured":"Committee for Medicinal Products for Human Use (CHMP) Guideline on immunogenicity assessment of monoclonal antibodies Intended for in vivo clinical use http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2012\/06\/WC500128688.pdf"},{"issue":"Suppl 1","key":"10.1111\/jcpt.12148-BIB0045|jcpt12148-cit-0045","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1186\/1478-6354-13-S1-S2","article-title":"Infliximab: 12\u00a0years of experience","volume":"13","author":"Smolen","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1111\/jcpt.12148-BIB0046|jcpt12148-cit-0046","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1002\/1529-0131(200011)43:11<2383::AID-ANR2>3.0.CO;2-D","article-title":"Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials","volume":"43","author":"Charles","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1111\/jcpt.12148-BIB0047|jcpt12148-cit-0047","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease","volume":"348","author":"Baert","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12148-BIB0048|jcpt12148-cit-0048","doi-asserted-by":"crossref","first-page":"609","DOI":"10.2165\/00002018-200831070-00006","article-title":"Influence of regulatory measures on the rate of spontaneous adverse drug reaction reporting in Italy","volume":"31","author":"Motola","year":"2008","journal-title":"Drug Saf"}],"container-title":["Journal of Clinical Pharmacy and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12148","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12148","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jcpt.12148\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T01:29:06Z","timestamp":1716600546000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jcpt.12148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,17]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,6]]}},"URL":"https:\/\/doi.org\/10.1111\/jcpt.12148","archive":["Portico"],"relation":{},"ISSN":["0269-4727"],"issn-type":[{"value":"0269-4727","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3,17]]}}}